No remarkable variations were observed in the OS of the patient groups based on factors such gender, age, smoking status, presence of brain metastasis, presence of bone metastasis, EGFR‐TKIs treatment line, and chemotherapy application (all p > 0.05) (Figure S1A–G). Here, EGFR is linked to bone metastasis.